A recent study indicates that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end traditional lifestyle regimens.
Published data in a major health publication points out that while obese individuals often shed a large proportion of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"People purchasing such treatments need to be informed of the risk of rapid rebound weight gain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
That rate of regain means a return to pre-treatment weight in about 18 months.
Analyzing Approaches
The analysis, which reviewed 37 of trials involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers point out that individuals who shed pounds through dieting typically have a slower creep back—approximately 100 grams monthly—after stopping.
Explaining the Fast Rebound
Doctors suggest the mechanism of the injections accounts for the heightened weight return.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing the hormone concentrations far above than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' means appetite is unsuppressed, making binge eating much more probable."
An Ongoing Issue?
Health authorities suggest the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Professionals say that, given the significant potential of relapse, the therapy is often life-long.
This view is supported by pharmaceutical companies, who say that the findings "highlight the chronic nature of excess weight," comparing it to managing diseases like hypertension.
Patient Testimonies
People who have come off the medication explain a intense resurgence of hunger.
"It was like something that goes on and you're instantly extremely hungry," described an individual.
This challenge is exacerbated if patients have not developed sustainable lifestyle or habit changes during therapy.
Growing Interest
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is higher among women compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Ultimately, researchers caution that while the jabs are powerful tools for weight loss, they are not a standalone solution and long-term success hinges on integrated lifestyle management.
